Managing Adults with Screen-Detected Islet Autoantibody Positivity: A Pragmatic Framework

Managing adults with screen-detected islet autoantibody positivity presents a significant challenge due to the lower risk of progression to type 1 diabetes compared to children, combined with a high background prevalence of mild non-autoimmune dysglycaemia. To address this issue, researchers from the University of Exeter Medical School proposed a pragmatic framework for managing adults with islet autoantibody positivity. This framework aims to provide clarity on international consensus guidelines and can be applied to various health systems, including the UK National Health Service.

Key Takeaways:

• The research highlights the need for a pragmatic framework to manage adults with islet autoantibody positivity, given the lower risk of progression to type 1 diabetes and the high background prevalence of mild non-autoimmune dysglycaemia.
• The proposed framework aims to add clarity to international consensus guidelines and provides a practical approach for clinicians to manage adults with islet autoantibody positivity.
• The framework is relevant to various health systems, including the UK National Health Service, and can be adapted to different settings.
• The study emphasizes the importance of islet autoantibody screening to identify individuals at increased risk of progression to diabetes.
• The research highlights the need for further studies to develop effective management strategies for adults with islet autoantibody positivity.

Statistics:

• The prevalence of islet autoantibody positivity in adults is estimated to be around 2-5% (Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework).
• The risk of progression to type 1 diabetes in adults with islet autoantibody positivity is lower compared to children, with an estimated 10-20% risk over 10 years (Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework).
• The background prevalence of mild non-autoimmune dysglycaemia in adults is estimated to be around 5-10% (Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework).

Sources:

• "Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework." Lancet Diabetes & Endocrinology, 2025; 13(11): 980-986.
• NewsRx. Studies from University of Exeter Medical School in the Area of Type 1 Diabetes Reported (Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework). Pediatrics Week. November 1, 2025; p 660.